Navigation Links
BioVigil Releases Second-Generation Hand Hygiene Monitoring System

SANTA ROSA, Calif., March 16 /PRNewswire/ -- BioVigil LLC has released the second generation of the BioVigil hand hygiene monitoring system. The innovative system enables hospitals to more effectively combat Hospital-Acquired Infections (HAIs) by dramatically increasing hand hygiene compliance among healthcare workers.  

HAIs waste over $20-30 billion each year, with as many as one in ten hospital patients picking up a secondary infection while spending time in a hospital. Infections are particularly dangerous for patients recovering from surgery, with as many as 99,000 deaths per year in the United States alone attributed to HAIs.

According to the U.S. Centers for Disease Control (CDC), hand hygiene is the single most effective way to combat hospital-acquired infections. As a result, 34 states have implemented standards which require hospitals to improve on hand hygiene.

The second-generation BioVigil system incorporates innovative badge technology and related sensors to effectively monitor hand hygiene compliance in hospitals. The system verifies the use of hand sanitizer in every patient's room, and records compliance data in a secure database.

"Our second-generation system solves the accuracy problems that are inherent in RF-based sensors," explains Brian Sheahan, Chief Executive Officer for BioVigil LLC. "An RF-based system does not have the accuracy and sensitivity which our system offers. We know with 100% accuracy when a healthcare worker enters and exits a location. Our system is simple, cost-effective and saves lives.

"In addition, the BioVigil system uses an alcohol sensor on the ID badge of the healthcare worker, so that a nurse or doctor can simply enter a patient's room, then use hand sanitizer while approaching the patient's bed and interacting with the patient. We have been able to design a sensor network which makes the system highly user-friendly and patient-friendly. The bright green and red LEDs embedded in the ID badge enable other healthcare personnel and even patients to easily see whether a healthcare worker is in compliance."

Mr. Sheahan noted that BioVigil completed an IRB-approved trial with VCU Medical Center during September 2009, validating the successful operation of its second-generation BV-140 technology. Dr. Michael Edmond of VCU Medical Center will be presenting results of the trial at the Society for Healthcare Epidemiology of America (SHEA) conference in Atlanta, GA on Sunday, March 21, 2010 at 11:45 a.m.

BioVigil (, based in Santa Rosa, California, has a number of patents which protect its proprietary approach at hand hygiene detection and reporting. The company has refined its unique approach to hand hygiene compliance over four years of development activity and repeated trials.    

    Joe Madden
    (707) 508-9170 

This release was issued through eReleases(TM).  For more information, visit


Back to top



Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Robert B. Arnot Releases White Paper on the Silent Threat of H1N1 and Other Infectious Diseases
2. Providence Service Corporation Releases Fourth Quarter and Year End 2009 Results
3. GeneGo Releases Content and Tools From Industry-FDA Driven MetaTox Partnership Via ToxHunter(TM)
4. Pi2 Solutions Releases the Latest Version of its Product Literature Database System for the Biopharmaceutical Industry
5. CEL-SCI Corporation Releases Letter to Shareholders
6. Berkery Noyes Releases 2009 Pharma and Healthcare Information Merger & Acquisition Trends
7. SpectraScience Releases Shareholder Newsletter
8. Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics
9. Lilly Releases Latest Value of Medicine Resource Guide About Key Issues Facing the Pharmaceutical Industry
10. ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists
11. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
Post Your Comments:
(Date:11/26/2015)... 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ... is expected to boost the market growth, as 3D bioprinting ... --> 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ...
(Date:11/26/2015)... 26, 2015 ... "2016 Future Horizons and Growth Strategies ... Market: Supplier Shares, Country Segment Forecasts, Competitive ... offering. --> ) has ... Future Horizons and Growth Strategies in the ...
(Date:11/26/2015)... PUNE, India , November 26, ... --> --> ... Research Report" and "Investigation Report on ... 2019 and 2021 forecasts data and ... library. . ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... largest, most successful and prominent nonprofit healthcare organizations in the country. They have ... with various organizations, and helped advance the healthcare industry as a whole through ...
(Date:11/27/2015)... ... ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces his search for ... of Joplin's most famous and beautiful concert posters. The concert was held on March ... The According to Hawley, "It is hard to believe that Joplin's stardom was only ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... abuse located in central Michigan, have come together on Thanksgiving Day to share ... video, available for viewing on the Serenity Point YouTube channel, patients displayed what ...
(Date:11/26/2015)... ON and Cambridge, ON (PRWEB) , ... November ... ... today the availability of a real-time eReferral system for diagnostic imaging in the ... ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
Breaking Medicine News(10 mins):